This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Alyssum Therapeutic S, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Aniruddha Sengupta: Innovator in Cancer Immunotherapy
Introduction
Aniruddha Sengupta is a prominent inventor based in Delhi, India. He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. His work focuses on advancing immunotherapy techniques to improve patient outcomes in cancer care.
Latest Patents
Aniruddha Sengupta holds a patent for a groundbreaking method in cancer treatment titled "B-cell immunotherapy in cancer treatment." This patent outlines methods for treating cancer in patients by administering a therapeutically effective amount of a specific compound, along with an immune checkpoint inhibitor. The compound, referred to as formula (VIII), is designed to enhance the effectiveness of cancer therapies. The patent emphasizes the importance of pharmaceutical compositions that include this compound and an immune checkpoint inhibitor, providing a novel approach to cancer treatment.
Career Highlights
Aniruddha Sengupta is associated with Alyssum Therapeutic S, Inc., where he continues to work on innovative solutions in the medical field. His dedication to research and development has positioned him as a key figure in the advancement of cancer therapies.
Collaborations
Aniruddha has collaborated with notable colleagues, including Shiladitya Sengupta and Sanghamitra Mylavarapu. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in cancer treatment.
Conclusion
Aniruddha Sengupta's contributions to cancer immunotherapy exemplify the impact of innovative thinking in medicine. His patent on B-cell immunotherapy represents a significant step forward in the fight against cancer, showcasing the potential of targeted therapies.